CA2992937A1 - Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie - Google Patents

Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie Download PDF

Info

Publication number
CA2992937A1
CA2992937A1 CA2992937A CA2992937A CA2992937A1 CA 2992937 A1 CA2992937 A1 CA 2992937A1 CA 2992937 A CA2992937 A CA 2992937A CA 2992937 A CA2992937 A CA 2992937A CA 2992937 A1 CA2992937 A1 CA 2992937A1
Authority
CA
Canada
Prior art keywords
her3
peptide
cell
peptides
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2992937A
Other languages
English (en)
Inventor
Brian J. CZERNIEKI
Gary K. Koski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041034 external-priority patent/WO2016011432A2/fr
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2992937A1 publication Critical patent/CA2992937A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

L'invention concerne des compositions, des méthodes et des vaccins qui peuvent stimuler le système immunitaire et qui peuvent être utilisés pour le traitement de tumeurs malignes associées à une surexpression de la protéine HER3. Ces compositions comprennent des épitopes de la protéine HER3.
CA2992937A 2015-07-17 2016-04-07 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie Abandoned CA2992937A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2015/041034 WO2016011432A2 (fr) 2014-07-17 2015-07-17 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
USPCT/US2015/041034 2015-07-17
PCT/US2016/021042 WO2017014810A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
USPCT/US2016/021042 2016-03-04
PCT/US2016/026542 WO2017014816A1 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Publications (1)

Publication Number Publication Date
CA2992937A1 true CA2992937A1 (fr) 2017-01-26

Family

ID=57835029

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2992925A Abandoned CA2992925A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
CA2992937A Abandoned CA2992937A1 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2992925A Abandoned CA2992925A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Country Status (5)

Country Link
EP (2) EP3325005A4 (fr)
JP (3) JP2018527286A (fr)
CN (1) CN107206045A (fr)
CA (2) CA2992925A1 (fr)
WO (2) WO2017014810A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325005A4 (fr) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
WO2021051066A1 (fr) * 2019-09-13 2021-03-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Thérapie par dc1 pulsées avec her3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
EP2258712A3 (fr) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
EP2400021B1 (fr) * 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. Procédés de type ErbB3 et compositions pour traiter des tumeurs malignes
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007115571A2 (fr) * 2006-04-07 2007-10-18 Enkam Pharmaceuticals A/S Fragments peptidiques dérivés du récepteur erbb
AU2007258874B2 (en) * 2006-06-15 2013-11-14 Seqirus UK Limited Adjuvant-sparing multi-dose influenza vaccination regimen
CN102326081B (zh) * 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
JP2010200693A (ja) * 2009-03-04 2010-09-16 Chiyoda Kako Kensetsu Kk 樹状細胞ワクチン製造用培養装置並びに樹状細胞の製造方法
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
EP2461828B1 (fr) * 2009-07-31 2017-06-21 President and Fellows of Harvard College Programmation de cellules à des fins de thérapie tolérogénique
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
KR102101806B1 (ko) * 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
AU2012349735B2 (en) * 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201601754A (zh) * 2013-09-30 2016-01-16 第一三共股份有限公司 核酸生物標記及其用途
EP3169354A4 (fr) * 2014-07-17 2018-06-13 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
EP3325005A4 (fr) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Also Published As

Publication number Publication date
EP3324990A4 (fr) 2019-04-03
CN107206045A (zh) 2017-09-26
EP3324990A1 (fr) 2018-05-30
EP3325005A1 (fr) 2018-05-30
EP3325005A4 (fr) 2019-03-27
JP2018521953A (ja) 2018-08-09
JP2021043204A (ja) 2021-03-18
WO2017014816A1 (fr) 2017-01-26
WO2017014810A1 (fr) 2017-01-26
CA2992925A1 (fr) 2017-01-26
JP2018527286A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
KR102515909B1 (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격
CN107912043B (zh) 用于食管癌和其他癌症免疫治疗的新型肽和肽组合物
US20210163573A1 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
KR20180121530A (ko) 비소세포 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
TR201900809T4 (tr) Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşi yeni immünoterapi.
KR20180127642A (ko) 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
RU2663350C2 (ru) Пептиды ube2t и содержащие их вакцины
KR20150046787A (ko) 암 줄기세포에서 발현하는 분자를 타깃으로 하는 암 진단 및 치료 방법
JP2020124193A (ja) 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
US9808504B2 (en) Immunogenic epitopes as targets for universal cancer vaccines
JP2021043204A (ja) 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
JP2016525498A (ja) Ｔｈ１細胞のＩＭＰ−３エピトープペプチドおよびこれを含有するワクチン
JP2015524652A (ja) Ｔｈ１細胞のＬＹ６Ｋエピトープペプチドおよびこれを含有するワクチン
TW201718624A (zh) 來自ｄｅｐｄｃ１之胜肽及含此之疫苗
AU2019201194B2 (en) Identification of immunogenic MHC Class II peptides for immune-based therapy
JP2018508181A (ja) Ｔｈ１細胞のためのＧＰＣ３エピトープペプチドおよびこれを含有するワクチン
TWI398262B (zh) 腫瘤相關抗原之免疫性肽類及其於癌症治療上的用途
CA2955456C (fr) Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
TW201443078A (zh) Ｃ１２ｏｒｆ４８胜肽及含此胜肽之疫苗
BR122023027394A2 (pt) Peptídeo, anticorpo, receptor de célula t, método de produção destes, ácido nucleico, célula hospedeira recombinante, linfócito t ativado, composição farmacêutica, seus usos e kit

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220628